+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
543500 EVOQ

Evoq Remedies Share Price

 

 

Evoq Remedies live price: ₹2.44. It opened at ₹2 vs previous close ₹3; intraday high/low: ₹2/₹2. The 50 & 200 DMA stand at ₹3.01/₹3.57.

Evoq Remedies Performance

  • Today's Low
  • ₹2
  • Today's High
  • ₹2
  • 52 Week Low
  • ₹2
  • 52 Week High
  • ₹6
  • Open Price₹2
  • Previous Close₹3
  • Volume68,000
  • 50 DMA₹3.01
  • 100 DMA₹3.15
  • 200 DMA₹3.57

Evoq Remedies Chart

Investment Returns

  • Over 1 Month -29.28%
  • Over 3 Month -6.87%
  • Over 6 Month -32.78%
  • Over 1 Year -54.39%

Smart Investing Starts Here Start SIP with Evoq Remedies for Steady Growth!

Invest Now

Evoq Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -25.3
  • PEG Ratio
  • -
  • Market Cap Cr
  • 6
  • P/B Ratio
  • 0.1
  • Average True Range
  • 0.19
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.18
  • RSI
  • 37
  • MFI
  • 11.79

Latest Stock News Updates

EVOQ Remedies tanks 16%, down 24% in two days after promoters' dramatic stake sale

On January 10, EVOQ Remedies said it secured a Rs 136- crore order, leading to a 20% spike in prices but soon promoters dumped 72% of their stake. It ended 8 percent lower on January 12

Evoq Remedies Financials

Evoq Remedies Technicals

EMA & SMA

Current Price
₹2.44
-0.12 (-4.69%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹2.80
  • 50 Day
  • ₹3.00
  • 100 Day
  • ₹3.20
  • 200 Day
  • ₹3.60

Resistance and Support

2.54 Pivot Speed
  • R3 2.64
  • R2 2.60
  • R1 2.58
  • S1 2.52
  • S2 2.48
  • S3 2.46

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Evoq Remedies has an operating revenue of Rs. 37.26 Cr. on a trailing 12-month basis. An annual revenue growth of 89% is outstanding, Pre-tax margin of -1% needs improvement, ROE of -0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 9 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 38 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Evoq Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-30 Half Yearly Results (Revised) to consider 1. Raising of funds upto Rs. 99.00 Crores by way of issue of Warrants. 2. Issuance of Equity shares other than cash through swap of shares. 3. Other business matters. (Revised)
2025-10-10 Quarterly Results
2025-05-06 Preferential issue of shares
2025-04-29 Others Rs.0.00 to consider 1. Raising of funds upto Rs. 99.00 Crores by way of issue of Warrants. 2. Issuance of Equity shares other than cash through swap of shares. 3. Other business matters. (Revised)
2025-04-10 Audited Results

Evoq Remedies Shareholding Pattern

0.02%
94.57%
5.41%

Evoq Remedies FAQs

Evoq Remedies share price is ₹2 As on 25 June, 2026 | 13:00

The Market Cap of Evoq Remedies is ₹6.1 Cr As on 25 June, 2026 | 13:00

The P/E ratio of Evoq Remedies is -25.3 As on 25 June, 2026 | 13:00

The PB ratio of Evoq Remedies is 0.1 As on 25 June, 2026 | 13:00

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23